7 Analysts Have This to Say About Pacific Biosciences
Portfolio Pulse from Benzinga Insights
Pacific Biosciences (NASDAQ:PACB) has received 7 analyst ratings in the last quarter, with 1 somewhat bullish and 6 indifferent. The average price target is $11.86, representing an upside from the current price of $7.98. This average is a decrease of 8.77% from the previous average price target of $13.00.
October 16, 2023 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pacific Biosciences has received mostly indifferent analyst ratings, with a somewhat bullish rating and an average price target of $11.86, indicating potential upside.
The indifferent analyst ratings suggest uncertainty about the company's performance. However, the somewhat bullish rating and the average price target above the current price indicate potential upside, which could positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100